CSL ASX: CSL says on track for double-digit growth but vaccine sales weak

CSL says on track for double-digit growth but vaccine sales weak
Michael SmithHealth editor
CSL says low immunisation rates in the United States hurt first-half sales for its vaccination business but a solid result for its core blood plasma
Read more...